| | Characteristic | SNS (110) | ANS (154) | P value |
| | Sex (male: female) | 88:22 | 72:82 | P<0.001 | | Age (years), median year (IQR) | 50 (44, 58) | 39 (30, 52) | P<0.001 | | ≤ 30 | 5, 4.5% | 42, 27.3% | NA | | 31~40 | 13, 11.8% | 37, 24.0% | NA | | 41~50 | 38, 34.5% | 31, 20.1% | NA | | 51~60 | 34, 30.9% | 33, 21.4% | NA | | ≥ 61 | 20, 18.2% | 11, 7.1% | NA | | Treatment history (yes: no) | 43:67 | 99:55 | P<0.001 | | Pretreatment serum RPR titer, median (IQR) | 1:32 (1:16, 1:64) | 1:32 (1:8, 1:64) | P=0.011 | | 1:1 (n, %) | 1, 0.9% | 0, 0% | NA | | 1:2 (n, %) | 0, 0% | 4, 2.6% | NA | | 1:4 (n, %) | 2, 1.8% | 10, 6.5% | NA | | 1:8 (n, %) | 14, 12.7% | 24, 15.6% | NA | | 1:16 (n, %) | 13, 11.8% | 29, 18.8% | NA | | 1:32 (n, %) | 32, 29.1% | 36, 23.4% | NA | | 1:64 (n, %) | 14, 12.7% | 28, 18.2% | NA | | 1:128 (n, %) | 12, 10.9% | 10, 6.5% | NA | | ≥1:256 (n, %) | 11, 10.0% | 6, 3.9% | NA | | Not available (n, %) | 11, 10.0% | 7, 4.5% | NA | | Current serum RPR titer, median (IQR) | 1:32 (1:8, 1:64) | 1:8 (1:8, 1:32) | P<0.001 | | 1:1 | 1, 0.9% | 0, 0% | NA | | 1:2 | 2, 1.8% | 9, 5.8% | NA | | 1:4 | 1, 0.9% | 16, 10.4% | NA | | 1:8 | 27, 24.5% | 53, 34.4% | NA | | 1:16 | 11, 10.0% | 30, 19.5% | NA | | 1:32 | 27, 24.5% | 28, 18.2% | NA | | 1:64 | 18, 16.4% | 14, 9.1% | NA | | 1:128 | 11, 10.0% | 1, 0.6% | NA | | ≥1:256 | 12, 10.9% | 3, 1.9% | NA | | Serum TPPA positive (n, %) | 110, 100% | 154, 100% | NA | | Serum FTA-ABS-IgG positive (n, %) | 110, 100% | 164, 100% | NA | | Serum FTA-ABS-IgM positive (n, %) | 35, 38.1% | 33, 24.1% | P=0.052 | | CSF RPR titer (positive: negative) | 90:20 | 45:109 | P<0.001 | | 1:1 | 24, 21.8% | 19, 12.3% | NA | | 1:2 | 24, 21.8% | 21, 13.6% | NA | | 1:4 | 22, 20.0% | 3, 1.9% | NA | | 1:8 | 13, 11.8% | 1, 0.6% | NA | | 1:16 | 6, 5.5% | 0, 0% | NA | | 1:32 | 1, 0.9% | 1, 0.6% | NA | | CSF WBC count, median (IQR), /ul | 10 (6, 33) | 7 (5, 11) | P<0.001 | | >5/ul (n, %) | 91, 82.7% | 125, 81.2% | P=0.746 | | CSF protein concentration, median (IQR), mg/dl | 56.2 (43.1, 76.8) | 35.3 (26.2, 46.6) | P<0.001 | | >45mg/dl (n, %) | 75, 68.1% | 44, 28.6% | P<0.001 | | CSF TPPA positive (n, %) | 110, 100% | 154, 100% | NA | | CSF FTA-ABS-IgG positive (n, %) | 110, 100% | 154, 100% | NA | | CSF FTA-ABS-IgM positive (n, %) | 1, 0.9% | 1, 0.6% | NA |
|
|
